Optimizing content for pre-exposure prophylaxis (PrEP) counseling for men who have sex with men: Perspectives of PrEP users and high-risk PrEP naïve men

AIDS and Behavior

Volumn 18, Issue 5, 2014, Pages 871-879

  Wade Taylor, S ^a   Mayer, Kenneth H ^a,b   Elsesser, Steven M ^a   Mimiaga, Matthew J ^a,c,d   O'Cleirigh, Conall ^a,c   Safren, Steven A ^a,c  

^a FENWAY INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adherence; Antiretroviral therapy for prevention; ART; HIV prevention; MSM; Pre exposure prophylaxis (PrEP)

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; COUNSELING; HIV INFECTIONS; HUMAN; INFORMATION PROCESSING; INTERVIEW; MALE; MALE HOMOSEXUALITY; MEDICATION COMPLIANCE; MOTIVATION; POST EXPOSURE PROPHYLAXIS; PROCEDURES; PSYCHOLOGY; QUALITATIVE RESEARCH; SOCIOECONOMICS; UNSAFE SEX;

ADULT; ANTI-HIV AGENTS; COUNSELING; FOCUS GROUPS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICATION ADHERENCE; MOTIVATION; POST-EXPOSURE PROPHYLAXIS; QUALITATIVE RESEARCH; SOCIOECONOMIC FACTORS; UNSAFE SEX;

EID: 84899584009     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-013-0617-7     Document Type: Article

References (42)

1. Kashuba ADM, Patterson KB, Dumond JB, Cohen MS. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet. 2012;379:2409-11.
2. Center for Disease Control and Prevention. HIV among gay and bisexual men: May 2012 Factsheet. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention: Division of HIV/AIDS Prevention. 2012.
3. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Presented at 20th Annual Conference on Retroviruses and Opportunist Infections; 2013 Mar 3-6; Atlanta, GA.
4. Muchomba FM, Gearing RE, Simoni JM, El-Bassel N. State of science of adherence in preexposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012;. doi: 10.1007/s10461-012-0172-7.
5. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-22.
6. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
7. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.
8. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-34.
9. Choopanya K, Martin M, Suntharasamai, et al, for the Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized double-blind, placebo controlled phase 3 trial. Lancet 2013; published online June 13. http://dx.doi.org/10.1016/S0140-6736(13)61127-7.
10. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention among heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
11. Haberer J, Baeten J, Celum C, Katibira E, Ronald A, Tumwesigye E, et al. High adherence among HIV-1 serodiscordant couples in the partners PrEP ancillary adherence study. Presented at 7th International Conference on HIV Treatment and Prevention Adherence; 2012 Jun 3-5; Miami, FL.
12. Safren SA, Otto MW, Worth JL. Life-Steps: applying cognitive behavioral therapy to HIV medication adherence. Cogn Behav Pract. 1999;6:332-41.
13. Safren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther. 2001;39(10):1151-62.
14. Psaros C, Haberer J, Thomas K, Katabira E, Ronald A, et al. Evaluation and process outcomes from an adherence intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in HIV serodiscordant couples in Uganda. Presented at 7th International Conference on HIV Treatment and Prevention Adherence; 2012 Jun 3-5; Miami, FL.
15. Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010;1:44-51.
16. Simoni JM, Chen WT, Huh D, Fredriksen-Goldsen KI, Pearson C, Zhao H, et al. A preliminary randomized controlled trial of a nurse-delivered medication adherence intervention among HIV-positive outpatients initiating antiretroviral therapy in Beijing, China. AIDS Behav. 2011;15(5):919-29.
17. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
18. Campbell C, Skovdal M, Mupambireyi Z, Madanhire C, Nyamukapa C, Gregson S. Building adherence-competent communities: factors promoting children's adherence to anti-retroviral HIV/AIDS treatment in rural Zimbabwe. Health Place. 2012;18(2):123-31.
19. Grohskopf L, Gvetadze R, Pathak S, O'Hara B, Mayer K, Liu A, et al. Phase II Clinical Safety Trial of Tenofovir Disoproxil Fumarate (TDF) for HIV-1 Pre-Exposure Prophylaxis (PrEP) Among U.S. Men who Have Sex with Men (MSM). Presented at XVIII International AIDS Conference; 2010 Jul 18-23; Vienna, Austria.
20. Sandelowski M. What's in a name? Qualitative description revisited. Res Nurs Health. 2010;33:77-84.
21. Sullivan-Bolyai S, Bova C, Harper D. Developing and refining interventions in persons with health disparities: the use of qualitative description. Nurs Outlook. 2005;53(3):127-33.
22. Miles MB, Huberman AM. An expanded sourcebook: qualitative data analysis. 2nd ed. Thousand Oaks: SAGE; 1994.
23. Ayres L, Kavanaugh K, Knafl KA. Within-case and across-case approaches to qualitative data analysis. Qual Health Res. 2003;13(6):871-83.
24. Lincoln YS, Guba EG. Naturalistic inquiry. Beverly Hills: SAGE; 1985.
25. Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz Aa. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011;23(9):1136-45.
26. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):2039-64.
27. Mugavero M, Ostermann J, Whetten K, Lesserman J, Swartz M, Thielman N. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20(6):418-28.
28. Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256-62.
29. Nezu A, D'Zurílla TJ. An experimental evaluation of the decision-making process in social problem solving. Cogn Ther Res. 1979;3:269-77.
30. Nezu A, D'Zurilla TJ. Effects of problem definition and formulation on decision-making in the social problem-solving process. Behav Ther. 1981;12:100-6.
31. Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep. 2007;4(4):165-72.
32. Supervie V, García-Lerma JG, Heneine W, Blower S. HIV transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA. 2010;107(27):12381-6.
33. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548-55.
34. Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, Chen PL, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35(12):1002-8.
35. Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, Grohskopf L, et al. No evidence of sexual risk compensation among HIV-uninfected men who have sex with men (MSM) participating in a tenofovir pre-exposure prophylaxis (PrEP) trial. Presented at 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 2011 Jul 17-20; Rome, Italy.
36. Marcus J, Mayer K, Guanira J, Casapia M, Montoya O, Chariyalertsak S, et al. No Evidence of Sexual Risk Compensation in the iPrEx Trial of HIV Pre-exposure Prophylaxis. Poster presented at: 20th Annual Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3-6; Atlanta, GA.
37. Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav. 2011;15:S72-9.
38. Liu AY, Grant RM, Buchbinder SP. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA. 2006;296:863-5.
39. Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet. 2007;370:89-93.
40. Strobos J, Hauschild B, Miller V. Safety Considerations in the Prevention of Transmission of HIV by Pre-Exposure Prophylaxis (or "PrEP"). Ann Forum Collab HIV Res. 2011;13(5):1-4.
41. Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH. Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep. 2010;7:210-9.
42. Carey MA. Comment: concerns in the analysis of focus group data. Qual Health Res. 1995;5(4):487-95.